Rhythm Pharmaceuticals Inc (STU:1RV)
€ 38.705 0.845 (2.23%) Market Cap: 2.43 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 41.42 GF Score: 52/100

Rhythm Pharmaceuticals Inc Bardet-Biedl and Alstrom Syndromes Phase 3 Data Corporate Call Transcript

Dec 22, 2020 / 01:00PM GMT
Release Date Price: €26.6 (+14.66%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Rhythm Pharmaceutical's conference call to discuss the Phase III data for setmelanotide in Bardet-Biedl and Alström syndromes. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, David Connolly, IR and Corporate Communications at Rhythm.

David Connolly
Rhythm Pharmaceuticals, Inc. - Head of IR & Corporate Communications

Thank you. Please go ahead, sir. Thank you, and thank you to everyone for joining us this morning as we discuss the positive top line results from our pivotal Phase III clinical trial evaluating setmelanotide in patients with Bardet-Biedl and Alström syndromes. Please note the press release issued earlier today and presentation we're using for this conference call are available online in the investors and media section of our website at rhythmtx.com.

Before we begin, I'd like to remind everybody that there will be forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot